ANO1 amplification's predictive value to adverse immunotherapeutic outcome retained for either GC (with statistical significance) or nonGC (EC+CRC+other cancers, with statistical tendency) (Figure S1B, Supporting Information). Here, ANO1 is linked to colorectal carcinoma.